ElleVet Sciences announced the launch of ElleVet Mobility, a supplement made from a proprietary hemp oil blend designed to support joint function and mobility in older dogs. The supplement comes in a soft chew form with added glucosamine and chondroitin and is available in two versions, sized for dogs over and under 50 pounds. The easy-to-digest products were moved into production for sale through veterinarian offices and online only after thorough testing was performed at one of the nation’s top veterinary colleges.
ElleVet partnered with Cornell University College of Veterinary Medicine to conduct the first pharmacokinetic study and clinical trial on the use of cannabinoids in dogs with osteoarthritis, using ElleVet’s proprietary hemp oil blend. Ellevet was the first to do a PK study and test the impact of cannabinoids on dogs with osteoarthritis. The results of the study brought unprecedented support for a hemp oil supplement for dogs from the veterinarians who administered the study. They referenced ElleVet’s product as “…a game changer that could change the face of veterinary medicine.” That sentiment from peer professionals has been echoed by the dog owners whose pets used the product in the study and in subsequent trials.
The impact of consumer reports combined with the success of the Cornell study galvanized ElleVet Science’s efforts to continue to uphold the empirical standards the company’s set for the products it produces. ElleVet is working to continue the scientific due diligence it has performed in the past with studies currently in the works in the areas of oncology and postoperative support as well as behavioral and anxiety support.
ElleVet Behavioral is already in the pipeline and is set for launch soon to support dogs with separation issues, nervous habits and destructive behaviors. Its development is following the same path of scientific scrutiny that achieved such dramatic results for ElleVet Mobility.